Behind the Breakthroughs

Human Longevity executive chairman Wei-Wu He discusses how the integration of genomics, advanced imaging, and artificial intelligence could transform disease prediction and personalized preventive medicine. Reflecting on Craig Venter’s legacy, he explores the challenges of democratizing precision medicine and the quest to extend human healthspan by identifying and intervening in disease before symptoms emerge.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)

Roche’s AXELIOS sequencer, Alzheimer’s blood test, and push to automate mass spectrometry point to a broader strategy of making advanced diagnostics routine. Whether AXELIOS can meaningfully challenge Illumina’s sequencing dominance, however, remains an open question.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)

Gene therapy’s biggest bottleneck remains delivery: getting increasingly sophisticated genetic medicines safely into the right cells. SonoThera is taking a radically different approach, using ultrasound and microbubbles instead of viral vectors and nanoparticles, which could allow for larger payloads, repeat dosing, and precise tissue targeting. The key question is whether this seemingly too-good-to-be-true approach can work in humans after promising results across multiple organs in animals.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)

Biocatalysis has evolved from a scientific curiosity into a powerful manufacturing platform, culminating in enlicitide, the first oral macrocyclic peptide PCSK9 inhibitor. Merck’s David Thaisrivongs explains how enzyme engineering helped create this “Goldilocks” class of medicines—and could open previously inaccessible drug targets to oral therapies.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)

Antimicrobial resistance (AMR) isn't going to be solved by new antibiotics alone—it also requires identifying resistant infections quickly enough to guide treatment and prevent transmission. In this episode of Behind the Breakthroughs, Anne Beaubrun, PhD, of Cepheid and Amish Acharya, PhD, of the Fleming Initiative, discuss how rapid molecular diagnostics, including the TRACE-CPE study, could bring precision medicine to infectious disease by enabling earlier detection of carbapenemase-producing Enterobacterales (CPE)—dangerous, last-resort antibiotic-resistant bacteria that are spreading rapidly in hospitals. They also explore the scientific, clinical, and policy challenges of making rapid diagnostics a routine part of healthcare worldwide.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)

For decades, psychiatry has relied on symptom-based diagnosis and trial-and-error treatment, but precision medicine is set to transform mental health care by using objective biological measures—such as EEG, sleep and circadian rhythm data, and cognitive testing—with AI-driven analysis to match patients with the therapies most likely to work for them. In this episode of Behind the Breakthroughs, Alto Neuroscience founder and CEO Amit Etkin explains how biomarker-guided drug development and biologically defined patient populations could make precision psychiatry routine, improving outcomes and changing how psychiatric disorders are diagnosed and treated.Produced and hosted by Jonathan D. Grinstein, PhDAudio mixed and mastered by Erick ZieglerBrought to you by Inside Precision Medicine (SAGE Publishing)